Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

Phase 4 Terminated 411 enrolled Brazilian Clinical Research Institute Beneficência Portuguesa de São Paulo · collab Brazilian Research In Intensive Care Network · collab Hospital Alemão Oswaldo Cruz · collab Hospital Israelita Albert Einstein · collab Hospital Moinhos de Vento · collab Hospital Sirio-Libanes · collab Hospital do Coracao · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.

Timeline

Start: 2021-03-04
Primary completion: 2022-05-13
Completion: 2022-05-30

Outcome

Outcome not reported

Stopped (Enrollment): “Due to the decrease in COVID cases and in the recruitment rate, and DSMB orientation.”

Publications

Santos BC, Flumignan RL, Civile VT, Atallah AN, Nakano LC. Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database Syst Rev. 2023 Aug 16;8(8):CD015102. doi: 10.1002/14651858.CD015102.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Apixaban	Small molecule	2.5 mg	Oral